SeekingAlpha · Sep 22, 2026
Immuron Limited (IMRN) Presents at Coffee Microcaps Conference 2026 - Slideshow
2026-09-22. The following slide deck was published by Immuron Limited in conjunction with this event.
IM
NASDAQ · IMRN
Immuron Limited
Healthcare · Biotechnology
$1.11
Down-$0.00 (-0.31%)
Updated Oct 9, 2026, 2:42 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 6.09M
- P/E ratio
- -1.74
- Dividend yield
- 0.00%
- 52-week range
- $0.70 – $1.99
- Volume
- 34.2K
- Avg. volume
- 545.45K
Price performance · IMRN
IMRN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
IMRN closed at $1.11 after 21 trading sessions, down 31.90% for the selected period.
- Last close
- $1.11
- Period change
- -31.90%
- Period low
- $1.07
- Period high
- $1.63
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $1.10 | $1.17 | $1.09 | $1.11 | 34.2K |
| Oct 7, 2026 | $1.052 | $1.15 | $1.052 | $1.09 | 40.82K |
| Oct 6, 2026 | $1.08 | $1.11 | $1.05 | $1.08 | 11.55K |
| Oct 5, 2026 | $1.08 | $1.10 | $1.05 | $1.07 | 37.97K |
| Oct 2, 2026 | $1.12 | $1.1299 | $1.08 | $1.09 | 89.28K |
| Oct 1, 2026 | $1.14 | $1.18 | $1.12 | $1.13 | 53.4K |
| Sep 30, 2026 | $1.18 | $1.18 | $1.15 | $1.16 | 83.3K |
| Sep 29, 2026 | $1.14 | $1.225 | $1.14 | $1.19 | 186.32K |
| Sep 28, 2026 | $1.16 | $1.185 | $1.14 | $1.16 | 38.84K |
| Sep 25, 2026 | $1.16 | $1.215 | $1.16 | $1.16 | 44.32K |
| Sep 24, 2026 | $1.17 | $1.24 | $1.17 | $1.19 | 60.53K |
| Sep 23, 2026 | $1.26 | $1.26 | $1.16 | $1.17 | 111.53K |
| Sep 22, 2026 | $1.27 | $1.285 | $1.18 | $1.255 | 177.25K |
| Sep 21, 2026 | $1.22 | $1.2995 | $1.19 | $1.24 | 146.97K |
| Sep 18, 2026 | $1.20 | $1.24 | $1.15 | $1.22 | 89.86K |
| Sep 17, 2026 | $1.19 | $1.244 | $1.15 | $1.18 | 125.39K |
| Sep 16, 2026 | $1.24 | $1.285 | $1.19 | $1.19 | 149K |
| Sep 15, 2026 | $1.34 | $1.40 | $1.23 | $1.24 | 286.01K |
| Sep 14, 2026 | $1.37 | $1.415 | $1.35 | $1.40 | 156.96K |
| Sep 11, 2026 | $1.60 | $1.67 | $1.42 | $1.45 | 468.85K |
| Sep 10, 2026 | $1.725 | $1.76 | $1.58 | $1.63 | 532.81K |
Latest IMRN news
The latest Smart Investors Daily articles mentioning IMRN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IMRN research
Overview
Company profile and research snapshot.
Company profile
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 18, 2017 | H.C. Wainwright | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 4, 2026
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and
Yahoo · Sep 4, 2026
IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today?
Immuron signed an agreement with Sweden’s Calmino Group to distribute digestive-health product Proibs in the U.S
Yahoo · Sep 4, 2026
Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement
Immuron (NASDAQ:IMRN) has secured exclusive U. S.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
